Mandated Part D Rebates Would Not Lead To Higher Premiums, Cost Shifts, MedPAC Commissioner Argues
This article was originally published in The Pink Sheet Daily
Executive Summary
In an online Health Affairs article, MedPAC commissioner Jack Hoadley and co-author Richard Frank rebut arguments against mandatory rebates on Medicare Part D drugs.
You may also be interested in...
Reimbursement News, In Brief
Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.